Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07278505 · ClinicalTrials.gov registry record · Phase 1
Study of Cannabidiol and Neuroimaging on Stress
A Phase 1 study of Stress and Trauma, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT07278505 is a Phase 1 study of Stress and Trauma that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 160 participants, below the 785-participant average among 152 other Stress trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07278505, a Phase 1 study of Stress and Trauma, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
Dysregulation in stress responsivity is a growing psychiatry-transdiagnostic fundamental phenomenon, with limited therapeutic strategies. With the legalization of medical and recreational cannabis, many people consume cannabidiol (CBD; a nonintoxicating cannabinoid) to alleviate stress response, without the benefit of scientific guidance. To address this gap, the investigators propose a rigorous translational neuroscience study in a clinical high-risk population to define the roles of CBD in stress response with mechanisms of mesocorticolimbic-network function and hierarchy, neurometabolic, endocrine, and behavior, building upon convergent evidence from animal models and human evidence from our laboratories.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol
Study Locations (1)
New York
- Ichan School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-10-28 |
| Est. Completion | 2030-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07278505
The ClinicalTrials.gov registry entry for NCT07278505 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 785-participant average among 152 other Stress trials with a reported enrollment target (80% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stress appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07278505 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07278505 about?
NCT07278505 is a clinical study titled "Study of Cannabidiol and Neuroimaging on Stress". Dysregulation in stress responsivity is a growing psychiatry-transdiagnostic fundamental phenomenon, with limited therapeutic strategies. With the legalization of medical and recreational cannabis, many people consume cannabidiol (CBD; a nonintoxicating cannabinoid) to alleviate stress response, wit...
What is the current status of trial NCT07278505?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2025-10-28. Estimated completion is 2030-02-28.
What conditions does trial NCT07278505 study?
This clinical trial studies the following conditions: Stress, Trauma, Early Life Adversity.
What interventions are being tested in trial NCT07278505?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT07278505?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07278505 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Cannabidiol on Stress and Nicotine Withdrawal
RECRUITING · Phase 1
-
Impact of OnabotulinumtoxinA (BOTOX®) on Stress
RECRUITING · Phase 1
-
Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures
COMPLETED · Phase 1
-
The Effects of Smell on Mood and Physical Responses
COMPLETED · Phase 1
-
Decreasing Stress and Improving Self-control With "Stress in Control" (Sync) Training
COMPLETED · Phase 1
-
Surviving Daily Life
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.